A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer.
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2018
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Adenocarcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Sponsors Genmab
- 25 Jun 2018 Status changed from not yet recruiting to recruiting.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2018 According to a Seattle Genetics media release, data from this trial will be presented at the American Society of Clinical Oncology 2018.